Persistent SARS-CoV-2 Infection in a Multiple Sclerosis Patient on Ocrelizumab: A Case Report.

Autor:	Ambadapoodi RS; Department of Neurology, University of Chicago Medical Center, Chicago, IL., Arnold FW; Division of Infectious Diseases, School of Medicine, University of Louisville, Louisville, KY., Chariker JH; Neuroscience Training Department, University of Louisville, Louisville, KY., Glynn A; Division of Infectious Diseases, School of Medicine, University of Louisville, Louisville, KY., Lauer W; Department of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY., Marimuthu S; Division of Infectious Diseases, School of Medicine, University of Louisville, Louisville, KY., Rouchka EC; Department of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY., Smith ML; Department of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY., Wolf LA; Division of Infectious Diseases, School of Medicine, University of Louisville, Louisville, KY.
Jazyk:	angličtina
Zdroj:	Research square [Res Sq] 2023 Apr 04. Date of Electronic Publication: 2023 Apr 04.
DOI:	10.21203/rs.3.rs-2768759/v1
Abstrakt:	A 44-year-old female patient with multiple sclerosis (MS) treated with ocrelizumab was hospitalized with SARS-CoV-2 pneumonia three times over the course of five months, eventually expiring. Viral sequencing of samples from her first and last admissions suggests a single persistent SARS-CoV-2 infection. We hypothesize that her immunocompromised state, due to MS treatment with an immunosuppressive monoclonal antibody, prevented her from achieving viral clearance. Competing Interests: Conflict of interest: The authors have no competing interests to declare that are relevant to the content of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu